Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, ...
Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep ...
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results